Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Dramatic Surge in Q4 Revenue; Losses Remain Flat

NEW YORK, Feb. 1 - Genaissance Pharmaceuticals on Friday posted a dramatic surge in fourth-quarter revenue and a relatively flat net loss compared with the same period one year ago.

 

Total revenue for the three months ended Dec. 31 were $2.2 million, a 289 percent increase over the $566,000 Genaissance posted one year ago.

 

R&D spending in the quarter dipped slightly to $12 million from $12.6 million in the year ago period, and the company reported a net loss of $11.4 million, or $.50 per share, compared with $11.3 million, or $.50 per share in the fourth quarter last year.

 

Genaissance had roughly $60 million in the bank at the end of fiscal 2001, it said.

"Last year we focused our attention on scaling up our technology and building the infrastructure to support our commercialization efforts," Kevin Rakin, president and CFO of Genaissance, said in statement. "With that completed, our resources are now focused on ... continuing to sign new partners from which we can obtain a recurring revenue stream as well as drug royalties."

 

Separately on Friday, Genaissance and Biogen struck a partnership that will marry Genaissance's pharmacogenomic tests with new drug targets and drugs currently in development at Biogen. The companies plan eventually to market the two in tandem.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.